Mugdha Tendulkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mugdha Tendulkar has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Reshma Tendulkar
Vivekanand Education Society's College of Pharmacy, Mumbai, India
6 shared publications - Alpa Yadav
Department of Chemistry, Ranchi University, Ranchi 834001, India
1 shared publication - Mukul Jain
Research and Development Cell, Parul University, Vadodara, India
1 shared publication - Nil Patil
Department of Life Sciences, Parul Institute of Applied Sciences, Parul University, Vadodara 391760, Gujarat, India
1 shared publication - Parmdeep Singh Dhanda
Department of Biochemistry, Punjab Agricultural University, Ferozepur Road, Ludhiana 141027, India
1 shared publication - Prashant Kaushik
Nagano University, 1088 Komaki, Ueda, Nagano 386-0031, Japan
1 shared publication
Latest Publications
- 9 January 2026
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 84 (2) , 1647-1663
Unveiling the Influence of Polyphenols on Mitogen-activated Protein Kinases in Cancer
- 9 January 2026
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 84 (2) , 1647-1663
Unveiling the Influence of Polyphenols on Mitogen-activated Protein Kinases in Cancer
- 1 January 2026
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 357, 112134
Enlarged cavum septum pellucidum & increased incidence of schizophrenia: Narrative review for neurodevelopmental correlate
- 1 January 2026
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 357, 112134
Enlarged cavum septum pellucidum & increased incidence of schizophrenia: Narrative review for neurodevelopmental correlate
- 20 December 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 115, 104795
Amalgamating artificial intelligence & neuropsychiatry: Multimodal approach for precision diagnosis
- 20 December 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 115, 104795
Amalgamating artificial intelligence & neuropsychiatry: Multimodal approach for precision diagnosis
- 20 November 2024
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 103, 104312
Childhood trauma & associated increased incidence of Alzheimer’s disease and its long-term structural effects on the brain
- 20 November 2024
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 103, 104312
Childhood trauma & associated increased incidence of Alzheimer’s disease and its long-term structural effects on the brain
- Open Access
Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice.
Open AccessUnveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice.
- Open Access
- 17 January 2023
- Published by Association for the International Development of Academic and Scientific Collaboration in AIDASCO Reviews
- Vol. 1 (1) , 14-17
Is Oncolytic Virotherapy a permanent cure for malignant gliomas?
Of all malignant glioma forms, glioblastoma is the most frequently present form. The treatment of this highly aggressive tumor form by applying conventional therapies is of low success, leading to a low survival rate. As representatives of immunotherapeutic agents, oncolytic viruses contribute to the revolution in cancer therapy. Although promising, the efficiency of oncolytic viruses for treating glioblastoma is also limited. This is a reason why further optimization of oncolytic virotherapy is necessary. In this work, we review some of glioblastoma's specificities and provide information about the current status of oncolytic virotherapy.
- 17 January 2023
- Published by Association for the International Development of Academic and Scientific Collaboration in AIDASCO Reviews
- Vol. 1 (1) , 14-17
Open AccessIs Oncolytic Virotherapy a permanent cure for malignant gliomas?
Of all malignant glioma forms, glioblastoma is the most frequently present form. The treatment of this highly aggressive tumor form by applying conventional therapies is of low success, leading to a low survival rate. As representatives of immunotherapeutic agents, oncolytic viruses contribute to the revolution in cancer therapy. Although promising, the efficiency of oncolytic viruses for treating glioblastoma is also limited. This is a reason why further optimization of oncolytic virotherapy is necessary. In this work, we review some of glioblastoma's specificities and provide information about the current status of oncolytic virotherapy.